DK2839004T3 - Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation - Google Patents
Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation Download PDFInfo
- Publication number
- DK2839004T3 DK2839004T3 DK13721452.4T DK13721452T DK2839004T3 DK 2839004 T3 DK2839004 T3 DK 2839004T3 DK 13721452 T DK13721452 T DK 13721452T DK 2839004 T3 DK2839004 T3 DK 2839004T3
- Authority
- DK
- Denmark
- Prior art keywords
- islands
- transplantation
- procedure
- term
- long
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625904P | 2012-04-18 | 2012-04-18 | |
| PCT/US2013/037150 WO2013158868A1 (en) | 2012-04-18 | 2013-04-18 | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2839004T3 true DK2839004T3 (da) | 2019-07-01 |
Family
ID=48326412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13721452.4T DK2839004T3 (da) | 2012-04-18 | 2013-04-18 | Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10081809B2 (enExample) |
| EP (1) | EP2839004B1 (enExample) |
| JP (2) | JP6348484B2 (enExample) |
| KR (1) | KR20150003824A (enExample) |
| CN (2) | CN104487574B (enExample) |
| AU (1) | AU2013249191B2 (enExample) |
| CA (1) | CA2870547A1 (enExample) |
| DK (1) | DK2839004T3 (enExample) |
| ES (1) | ES2732252T3 (enExample) |
| IN (1) | IN2014DN08158A (enExample) |
| MX (1) | MX370149B (enExample) |
| NZ (1) | NZ630914A (enExample) |
| RU (1) | RU2667960C2 (enExample) |
| WO (1) | WO2013158868A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| US9791442B2 (en) | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| EP2940115B1 (en) * | 2014-04-30 | 2018-10-17 | The Procter and Gamble Company | Cleaning composition |
| RU2016147569A (ru) | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| ES2718380T3 (es) * | 2015-10-29 | 2019-07-01 | Procter & Gamble | Composición detergente líquida |
| EP3162878A1 (en) * | 2015-10-29 | 2017-05-03 | The Procter and Gamble Company | Liquid detergent composition |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| CN112840025A (zh) * | 2018-05-08 | 2021-05-25 | 迈阿密大学 | 用于将治疗性核酸递送到组织的材料方法 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| SI1456380T1 (sl) * | 2001-11-02 | 2012-11-30 | Giuliani Int Ltd | Smad inhibitorji za zdravljenje cns bolezni |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2905724T3 (es) | 2003-06-13 | 2022-04-11 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| GB0326778D0 (en) * | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
| RU2434942C2 (ru) * | 2004-09-28 | 2011-11-27 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний |
| JP4991547B2 (ja) | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| AU2009237577B2 (en) * | 2008-04-18 | 2014-06-05 | Baxter Healthcare Sa | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| US9791442B2 (en) | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| EP2970419B8 (en) | 2013-03-15 | 2019-12-11 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| RU2016147569A (ru) | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| EP3213070A2 (en) | 2014-10-17 | 2017-09-06 | Nogra Pharma Limited | Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| WO2017055611A2 (en) | 2015-09-30 | 2017-04-06 | Nogra Pharma Limited | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
| JP2019507755A (ja) | 2016-02-24 | 2019-03-22 | ノグラ ファーマ リミテッド | Ｓｍａｄ７阻害を使用するセリアック病の処置の方法 |
| WO2018122376A1 (en) | 2016-12-30 | 2018-07-05 | Nogra Pharma Limited | Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis |
-
2013
- 2013-04-18 CN CN201380020520.2A patent/CN104487574B/zh not_active Expired - Fee Related
- 2013-04-18 KR KR1020147032172A patent/KR20150003824A/ko not_active Abandoned
- 2013-04-18 JP JP2015507173A patent/JP6348484B2/ja not_active Expired - Fee Related
- 2013-04-18 DK DK13721452.4T patent/DK2839004T3/da active
- 2013-04-18 MX MX2014012650A patent/MX370149B/es active IP Right Grant
- 2013-04-18 NZ NZ630914A patent/NZ630914A/en not_active IP Right Cessation
- 2013-04-18 AU AU2013249191A patent/AU2013249191B2/en not_active Ceased
- 2013-04-18 US US14/394,999 patent/US10081809B2/en not_active Expired - Fee Related
- 2013-04-18 ES ES13721452T patent/ES2732252T3/es active Active
- 2013-04-18 CA CA2870547A patent/CA2870547A1/en not_active Abandoned
- 2013-04-18 RU RU2014146170A patent/RU2667960C2/ru not_active IP Right Cessation
- 2013-04-18 CN CN201710440085.9A patent/CN107252492A/zh active Pending
- 2013-04-18 EP EP13721452.4A patent/EP2839004B1/en active Active
- 2013-04-18 WO PCT/US2013/037150 patent/WO2013158868A1/en not_active Ceased
- 2013-04-18 IN IN8158DEN2014 patent/IN2014DN08158A/en unknown
-
2018
- 2018-05-31 JP JP2018104372A patent/JP2018131468A/ja active Pending
- 2018-08-10 US US16/100,906 patent/US10443056B2/en not_active Expired - Fee Related
-
2019
- 2019-09-04 US US16/559,974 patent/US20200239884A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10443056B2 (en) | 2019-10-15 |
| JP2015514778A (ja) | 2015-05-21 |
| CA2870547A1 (en) | 2013-10-24 |
| MX370149B (es) | 2019-12-03 |
| AU2013249191A1 (en) | 2014-10-09 |
| NZ630914A (en) | 2017-01-27 |
| RU2667960C2 (ru) | 2018-09-25 |
| CN107252492A (zh) | 2017-10-17 |
| CN104487574B (zh) | 2017-07-07 |
| US20190136237A1 (en) | 2019-05-09 |
| US10081809B2 (en) | 2018-09-25 |
| EP2839004A1 (en) | 2015-02-25 |
| US20150315573A1 (en) | 2015-11-05 |
| AU2013249191B2 (en) | 2019-01-03 |
| HK1207117A1 (en) | 2016-01-22 |
| ES2732252T3 (es) | 2019-11-21 |
| IN2014DN08158A (enExample) | 2015-05-01 |
| US20200239884A1 (en) | 2020-07-30 |
| RU2014146170A (ru) | 2016-06-10 |
| KR20150003824A (ko) | 2015-01-09 |
| MX2014012650A (es) | 2015-04-08 |
| JP2018131468A (ja) | 2018-08-23 |
| EP2839004B1 (en) | 2019-06-12 |
| JP6348484B2 (ja) | 2018-06-27 |
| CN104487574A (zh) | 2015-04-01 |
| WO2013158868A1 (en) | 2013-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3295942T3 (da) | Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion | |
| DK2855667T3 (da) | Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3366307T3 (da) | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri | |
| DK3677271T3 (da) | Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
| DK2638149T3 (da) | Immortalisering af epitelceller og fremgangsmåder til anvendelse | |
| DK2838900T3 (da) | Forbindelser og fremgangsmåder til antiviral behandling | |
| DK2753187T4 (da) | Fremgangsmåde til forebyggelse og/eller behandling af insulinresistens | |
| DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| DK2892912T3 (da) | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf | |
| DK2658965T3 (da) | Fremgangsmåde til fremstilling af inducerede pluripotente stamceller og differentierede celler | |
| DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
| DK2867422T3 (da) | Anordning til armering af sammenføjninger og søjler i kombination | |
| DK2882444T3 (da) | Mikroporøs zirconiumsilikat til behandling af hyperkaliæmi | |
| DK2771022T3 (da) | Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| DK3080353T3 (da) | Fremgangsmåde til oprensning og isolering af lignin | |
| DK2702992T3 (da) | Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis | |
| DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK2864473T3 (da) | Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus |